Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma (NCT07176650)

🧪 Interventions in This Study

• HLX13 (DRUG)
• Yervoy (DRUG)
• OPDIVO (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (51 Sites)

Showing the first 25 of 51 sites.

• Oncology Physicians Network (OPN) - Los Alamitos /OPN Healthcare — Glendale, California
• Los Angeles Cancer Network — Glendale, California
• Cancer Specialists of North Florida — Jacksonville, Florida
• D&H National Research Centers, LLC — Margate, Florida
• Mid Florida Hematology and oncology Center — Orange City, Florida
• Florida Clinical Trials Group — Plantation, Florida
• Florida Clinical Trials Group — Tamarac, Florida
• HCA Research Institute, LLC — Brentwood, Tennessee
• Oncology Consultants — Houston, Texas
• American Oncology Network Vista Oncology Division/Physician Partner Associate — Olympia, Washington
• Northwest Medical Specialties PLLC (NWMS) — Tacoma, Washington
• Cancer Hospital Chinese Academy of Medical Sciences — Beijing,
• Peking Union Medical College Hospital — Beijing,
• Peking university international hospital — Beijing,
• The First Affiliated Hospital of Bengbu Medical University — Bengbu,
• JiLin Cancer Hospital — Changchun,
• The First Hospital of Jilin University — Changchun,
• People's Hospital of Hunan Province — Changsha,
• Chengdu Fifth People's Hospital — Chengdu,
• Sichuan Cancer Hospital — Chengdu,
• Dongguan People's Hospital — Dongguan,
• Fujian Cancer Hospital — Fuzhou,
• Ganzhou People's Hospital — Ganzhou,
• Nanfang Hospital, Southern Medical University — Guangzhou,
• Hainan General Hospital — Haikou,

📞 Contact the Study Coordinator

Phone: +86-021-33395800

Email: Xuhui_Hu@henlius.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Hepatocellular Carcinoma (HCC)

• Streamlined Resin Y90 Radiation Segmentectomy for Small HCC — Chapel Hill, North Carolina
• A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE — Aurora, Colorado
• Utilize Imaging to Assess Changes in Hepatocellular Carcinoma Perfusion as Potentiated by Intra-Arterial Nitroglycerin — San Francisco, California
• Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellular Carcinoma. — Hamilton, Ontario
• Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant — London, Ontario
• Liquid Biopsy for Hepatocellular Carcinoma Molecular Characterization After Y90 — Palo Alto, California

Explore by condition: All Hepatocellular Carcinoma (HCC) clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.